Literature DB >> 17622362

Prognostic value of 6-minute walk test in stable outpatients with heart failure.

Sakir Arslan1, Mustafa Kemal Erol, Fuat Gundogdu, Serdar Sevimli, Enbiya Aksakal, Huseyin Senocak, Necip Alp.   

Abstract

The study was designed to evaluate the prognostic value of the 6-minute walk test in stable outpatients with heart failure. We prospectively studied 43 patients (6 women and 37 men) who had chronic heart failure secondary to ischemic heart disease or idiopathic cardiomyopathy. All patients had left ventricular systolic dysfunction (ejection fraction, < or = 0.40), and they were in stable New York Heart Association functional class II or III heart failure. All patients were evaluated by M-mode and 2-dimensional echocardiography. At the outset, walking distances of all the patients were evaluated by the 6-minute walk test. The patients were divided into 2 groups: Group I, patients with a 6-minute walk test distance of < or = 300 m; and Group II, patients with a 6-minute walk test distance of > 300 m. The patients were then monitored for a period of 2 years in regard to cardiac death. The mortality rate was significantly higher in patients with a 6-minute walk test distance of < or = 300 m than in patients with a 6-minute walk test distance of > 300 m (79% vs 7%; P <0.001). The death risk was found to be significantly higher in patients with a distance of < or = 300 m (P=0.005). The death risk was also higher in patients whose left ventricular ejection fraction was < or = 0.30 (P=0.02). We conclude that a 6-minute walk test distance of < or = 300 m is a simple and useful prognostic marker of subsequent cardiac death in patients with mild-to-moderate heart failure.

Entities:  

Mesh:

Year:  2007        PMID: 17622362      PMCID: PMC1894714     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  18 in total

1.  Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice?

Authors:  C Opasich; G D Pinna; A Mazza; O Febo; R Riccardi; P G Riccardi; S Capomolla; G Forni; F Cobelli; L Tavazzi
Journal:  Eur Heart J       Date:  2001-03       Impact factor: 29.983

2.  The six-minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure.

Authors:  L P Cahalin; M A Mathier; M J Semigran; G W Dec; T G DiSalvo
Journal:  Chest       Date:  1996-08       Impact factor: 9.410

3.  Prognosis in patients with low left ventricular ejection fraction after myocardial infarction. Importance of exercise capacity.

Authors:  L Pilote; J Silberberg; R Lisbona; A Sniderman
Journal:  Circulation       Date:  1989-12       Impact factor: 29.690

4.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

5.  [Prognostic value of the Six-Minute Walk Test in heart failure].

Authors:  Valéria Siqueira Martins Rubim; Cantídio Drumond Neto; José Luiz Martins Romeo; Marcelo Westerlund Montera
Journal:  Arq Bras Cardiol       Date:  2006-02-20       Impact factor: 2.000

6.  Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure.

Authors:  J Myers; L Gullestad; R Vagelos; D Do; D Bellin; H Ross; M B Fowler
Journal:  Ann Intern Med       Date:  1998-08-15       Impact factor: 25.391

7.  Spectrum and outcome of congestive heart failure in a hospitalized population.

Authors:  B Andersson; F Waagstein
Journal:  Am Heart J       Date:  1993-09       Impact factor: 4.749

8.  Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators.

Authors:  V Bittner; D H Weiner; S Yusuf; W J Rogers; K M McIntyre; S I Bangdiwala; M W Kronenberg; J B Kostis; R M Kohn; M Guillotte
Journal:  JAMA       Date:  1993-10-13       Impact factor: 56.272

9.  Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.

Authors:  J N Cohn; G R Johnson; R Shabetai; H Loeb; F Tristani; T Rector; R Smith; R Fletcher
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

10.  Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure.

Authors:  D M Mancini; H Eisen; W Kussmaul; R Mull; L H Edmunds; J R Wilson
Journal:  Circulation       Date:  1991-03       Impact factor: 29.690

View more
  33 in total

1.  Program description: physical therapy in a heart failure clinic.

Authors:  Ann Knocke
Journal:  Cardiopulm Phys Ther J       Date:  2012-09

2.  Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.

Authors:  Joseph Pidala; Xiaoyu Chai; Paul Martin; Yoshihiro Inamoto; Corey Cutler; Jeanne Palmer; Daniel Weisdorf; Steven Pavletic; Mukta Arora; Madan Jagasia; David Jacobsohn; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-03-27       Impact factor: 5.742

3.  Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION).

Authors:  Robert J Mentz; Vera Bittner; Phillip J Schulte; Jerome L Fleg; Ileana L Piña; Steven J Keteyian; Gordon Moe; Anil Nigam; Ann M Swank; Anekwe E Onwuanyi; Meredith Fitz-Gerald; Andrew Kao; Stephen J Ellis; William E Kraus; David J Whellan; Christopher M O'Connor
Journal:  Am Heart J       Date:  2013-07-12       Impact factor: 4.749

Review 4.  End points in heart failure-are we doing it right?

Authors:  Luxitaa Goenka; Melvin George; Sandhiya Selvarajan
Journal:  Eur J Clin Pharmacol       Date:  2017-03-09       Impact factor: 2.953

5.  Phenotype of normal spirometry in an aging population.

Authors:  Carlos A Vaz Fragoso; Gail McAvay; Peter H Van Ness; Richard Casaburi; Robert L Jensen; Neil MacIntyre; Thomas M Gill; H Klar Yaggi; John Concato
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

6.  Nocturia, sleep and daytime function in stable heart failure.

Authors:  Nancy S Redeker; Laura Adams; Robert Berkowitz; Lenore Blank; Ronald Freudenberger; Michele Gilbert; Joyce Walsleben; Mark J Zucker; David Rapoport
Journal:  J Card Fail       Date:  2012-07       Impact factor: 5.712

7.  Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION).

Authors:  Robert J Mentz; Phillip J Schulte; Jerome L Fleg; Mona Fiuzat; William E Kraus; Ileana L Piña; Steven J Keteyian; Dalane W Kitzman; David J Whellan; Stephen J Ellis; Christopher M O'Connor
Journal:  Am Heart J       Date:  2012-11-28       Impact factor: 4.749

Review 8.  Possibilities and Implications of Using the ICF and Other Vocabulary Standards in Electronic Health Records.

Authors:  Daniel J Vreeman; Christophe Richoz
Journal:  Physiother Res Int       Date:  2013-07-30

9.  The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium.

Authors:  Bartolome Celli; Kay Tetzlaff; Gerard Criner; Michael I Polkey; Frank Sciurba; Richard Casaburi; Ruth Tal-Singer; Ariane Kawata; Debora Merrill; Stephen Rennard
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

10.  Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.

Authors:  Ashvarya Mangla; John Kane; Elijah Beaty; DeJuran Richardson; Lynda H Powell; James E Calvin
Journal:  Am J Cardiol       Date:  2013-09-21       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.